Syndax Pharmaceuticals has entered a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo (axatilimab-csfr), a treatment for chronic graft-versus-host disease ...

To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax ...

Good day, everyone, and welcome to the Syndax Third Quarter 2024 Earnings Conference Call. Today's call is being recorded. All participants have been placed in a listen-only mode. You'll have an ...

The US regulator has cleared the anti-CSF-1R antibody under the Niktimvo brand for the treatment of chronic GvHD after failure of at least two prior lines of systemic therapy in adult and ...

Revumenib NDA in R/R KMT2Ar acute leukemia is being reviewed under RTOR; PDUFA action date of December 26, 2024 – – Niktimvo approved by U.S. FDA for treatment of chronic GVHD after failure of at ...

Q3 2024 Earnings Call Transcript October 29, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $1.07 ...

The company also highlighted several key updates from their pipeline, including the FDA approval for Niktimvo (axatilimab-csfr) for chronic graft-versus-host disease (GVHD). So, despite the EPS mi ...

1. Axatilimab (Niktimvo) received FDA approval for third-line treatment of chronic graft-versus-host disease (cGVHD) earlier than expected. The company plans to launch the drug in late 2024 or ...

Total revenues of $1,138 million in the third quarter (Q3'24) (+24% Y/Y) Jakafi ® (ruxolitinib) net product revenues of $741 ...

Syndax Pharmaceuticals (Nasdaq: SNDX) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Syndax has entered into a $350 million synthetic royalty funding agreement with Royalty Pharma based on ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...